论文部分内容阅读
1有效成份沙美特罗（salmetero），氟替卡松丙酸酯（flutlcasoneproplonate）2剂型口腔用干粉吸人剂3开发与上市厂商（英）GlaxoWellome公司研制，1999年4月在英国上市。4作用特点本剂系沙美特罗和氟替卡松丙酸酯组成的复方制剂，因两种成份的作用机制互补故临床效果良好。本剂
1 active ingredients salmetero, fluticasone propionate (flutlcasoneproplonate) 2 formulations of oral dry powder inhaler 3 development and listing of manufacturers (British) GlaxoWellome company developed in April 1999 in the UK. 4 The characteristics of the agent Salmeterol and fluticasone propionate composition of the compound, due to the interaction of the two components of the mechanism so that the clinical effect is good. This agent